Diabetes to become most expensive disease
A doctor (L) checks the blood sugar level of a passerby at a free blood sugar level check-up camp.
TEXT OF INTERVIEW
Tess Vigeland: A new study's out today from the insurance company UnitedHealth about the economic cost of diabetes in this country. And where do I begin?
Diabetes is projected to cost $500 billion by 2020. That's a tenth of all health care spending -- $3.4 trillion in total costs over the next 10 years. I read those numbers and asked Gregory Warner to parse them from our Marketplace health desk at WHYY. Hi Gregory.
GREGORY WARNER: Hi Tess.
Vigeland: Tell me a little bit about this study first of all: how does diabetes cost so much?
WARNER: Well basically if you break down the numbers pretty roughly, about a sixth of that money goes actually to treat diabetes and another third goes to diabetes-related diseases and complications like heart disease. But then a lot of the burden of disease is actually not medical; it's just things like lost productivity and extra time and money spent by families for care. And when you consider the number of people with diabetes, and the age getting younger and younger, that's when the costs start adding up.
Vigeland: Boy, apparently they really do. But still -- a tenth of the country's health care spending is going to diabetes? That's the prediction here. That would make diabetes the most expensive disease there is, wouldn't it?
WARNER: Yeah, when you factor in all the costs, it might be. But curiously, as I researched this, Alzheimer's is also up there. Again, because of all the complicating factors: the extra care, the nursing homes, and unpaid time to spouses and children. I talked to Joel Hay, he's an economist at the University of Southern California:
Joel Hay: Alzheimer's and diabetes, if nothing changes, will bankrupt our society. And whether we go through diabetes or Alzheimer's, I think it's kind of moot.
Vigeland: Gregory, he sounds almost cheerful there.
WARNER: Well there's a gallows humor shared by most health economists.
Vigeland: But he does bring up a good question. I read these numbers, I don't want bankruptcy, but what am I supposed to do?
WARNER: Well right, because you're not going to read $500 billion and then not buy a sugar doughnut.
Vigeland: Well maybe I would.
WARNER: You would, Tess. The rest of us, I'm not sure. Ultimately, though, who do these numbers matter to? They matter to Congress; these are the numbers that end up in the first paragraph of those congressional reports. And even more importantly, they're the numbers considered by the NIH -- the National Institutes for Health -- when they decide how to allocate research dollars. I mean, in fact, the best example of this might be the early estimates of the costs of HIV/AIDS in the late '80s. Those numbers turned out to be totally overblown, but they resulted in a huge amount of dollars -- way more than was spent on cancer and any other disease -- pouring in and now, look, we have a disease that was once a death sentence. It's now something you can live with if you have access to the meds.
Vigeland: So you talk about the cost, and you build up the funding.
WARNER: Exactly. And as you mentioned, people do get numb to all these numbers, hearing about the billions, the trillions. So there's also this image problem that the disease has. A number of advocacy organizations, because next month is National Diabetes Month, they're prepping campaigns that are going to emphasize that you can die from diabetes -- you know, heart disease, heart failure, organ failure. So they want to change that image of diabetes as something you sort of shuffle around with to something that you die from. Look, telling people that you're going to die does sometimes change their behavior, but it definitely raises funding.
Vigeland: All right. Marketplace's Gregory Warner joining us from Philadelphia. Thanks.
WARNER: Thanks Tess.